SLU-PP-332
Research OnlyA small molecule ERR (Estrogen-Related Receptor) agonist developed at Saint Louis University. Preclinical studies suggest exercise-mimetic properties, but no human data exists. Represents early-stage research into pharmacologically activating exercise pathways.
ERR agonist 332 · Exercise mimetic compound
Preclinical evidence only
- Preclinical
- 63%
- Human research
- 0%
Based on 8 cited sources
Numeric assessment unreviewed
A historical numeric score is recorded but has not passed a current, compound-specific assessment review. No numeric score is displayed.
This is a limitation of the numeric assessment, not a measured absence of benefit. It does not re-review the separately recorded catalogue classification or establish efficacy or safety.
The proposed mechanisms of SLU-PP-332 are based entirely on animal and in vitro studies. No human mechanistic data exists, and this compound has never been tested in humans.
How It Works (Simplified)
SLU-PP-332 aims to activate “exercise pathways” pharmacologically by targeting ERR receptors:
Binds to ERRalpha and ERRgamma receptors, triggering transcription of metabolic genes normally activated by exercise.
Promotes PGC-1alpha coactivation, signaling cells to build more mitochondria and enhance energy production capacity.
Upregulates genes for fatty acid oxidation and oxidative phosphorylation, enhancing aerobic energy pathways.
In mice, these changes translated to improved treadmill endurance and reduced muscle fatigue markers.
Key Research: Billon C et al. (Saint Louis University, 2023) demonstrated ERR-mediated endurance enhancement in mouse models. PMID:36988910
Important Limitations
- Mouse-only data - SLU-PP-332 has never been tested in humans
- Single research group - Most data originates from one laboratory
- Pharmacokinetics unknown - No data on absorption, metabolism, or distribution in humans
- Long-term safety unknown - Chronic ERR activation effects are uncharacterized
- Research compound only - Not manufactured to pharmaceutical standards
- Translation uncertain - Mouse exercise physiology differs substantially from humans
Based on mouse studies: ERR target gene activation may begin within days. Changes in oxidative gene expression observed in animal models. No human timeline data available.
PMID:36988910Mouse studies suggest mitochondrial biogenesis markers increase over this timeframe. PGC-1alpha pathway activation observed. Human response completely unknown.
PMID:20418374In mouse endurance studies, functional improvements in running capacity observed by 4-8 weeks. Translation to human physiology is entirely speculative.
PMID:36988910Long-term effects unknown. Chronic ERR activation has not been studied in any species for extended periods. Safety of prolonged use is completely uncharacterized.
Research-based observations
This timeline reflects observations from published clinical and preclinical studies. Individual responses may vary significantly. This is not a guarantee of effects or a dosing schedule. Consult qualified healthcare providers for personalized guidance.
Metformin
CompatibleDifferent mechanisms (metformin primarily affects hepatic gluconeogenesis and AMPK, SLU-PP-332 targets ERR in muscle). Theoretical complementary effects but no combined studies.
BPC-157
CompatibleNon-overlapping mechanisms. BPC-157 focuses on tissue repair while SLU-PP-332 targets metabolic pathways. No known contraindications.
TB-500
CompatibleNon-overlapping mechanisms. TB-500 focuses on tissue repair and cell migration while SLU-PP-332 targets ERR-mediated metabolic pathways. No interaction data available.
Aicar
CautionBoth target exercise-mimetic pathways (AICAR via AMPK, SLU-PP-332 via ERR). Combined activation of these parallel pathways has not been studied. Theoretical synergy but unknown safety profile.
Sr9009
CautionBoth target metabolic enhancement through nuclear receptor modulation (SR9009 via REV-ERB, SLU-PP-332 via ERR). No interaction data available. Exercise caution with combined metabolic modulators.
Gw501516
AvoidGW501516 development was halted due to cancer concerns in animal studies. Combining with another metabolic modulator increases theoretical risk. Neither compound has human safety data.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
Key Studies Cited
Use the source links in the research discussion above to inspect the referenced records.
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength labels summarize the cited material for this entry and should be read alongside its population, model, and study limitations.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare SLU-PP-332
Related Peptides
5-Amino-1MQ
5-Amino-1-Methylquinolinium · NNMT Inhibitor
A small molecule NNMT inhibitor studied for metabolic effects in animal models. No human clinical trials have been conducted. Increases NAD+ levels in adipose tissue in preclinical studies.
Amycretin
NNC0487-0111 · Oral Amycretin · Subcutaneous Amycretin
A novel single-molecule dual GLP-1/amylin receptor agonist developed by Novo Nordisk. Unlike CagriSema (a fixed-dose combination), amycretin is a unified peptide that activates both pathways. Phase 1 trials showed superior weight loss signals versus semaglutide, with both oral and subcutaneous formulations in development.
AOD-9604
Anti-Obesity Drug 9604 · Tyr-hGH Fragment 177-191
AOD-9604 is a modified human-growth-hormone fragment investigated for obesity and fat metabolism. Its obesity development program did not establish efficacy, and current regulatory sources identify major safety and quality gaps for unapproved or compounded products.
Cagrilintide
AM833 · NN9838
Investigational long-acting amylin analogue. REDEFINE 1 included a Phase 3 cagrilintide-only arm; Novo reports 11.8% mean weight loss versus 2.3% with placebo at 68 weeks using an on-treatment estimand. Dedicated RENEW Phase 3 monotherapy trials have started. Cagrilintide is also a CagriSema component.
CagriSema
Cagrilintide-Semaglutide · NNC0174-0833
Investigational fixed-dose cagrilintide plus semaglutide combination. Novo filed a US obesity NDA in December 2025. Its sponsor-reported REDEFINE 4 head-to-head trial missed non-inferiority versus tirzepatide; September 2026 REIMAGINE 5 and REDEFINE 9 toplines address different populations and doses. A filing and positive toplines are not FDA approval.
CT-388
RG-6912
A dual GLP-1/GIP receptor agonist (INN enicepatide; also RO7795068) acquired by Roche through the $2.7 billion Carmot Therapeutics acquisition in 2024. The published Phase 1 trial (NCT04838405) showed 4.7-8.0% mean weight loss vs 0.5% placebo over 4 weeks; a more widely reported ~18.8% placebo-adjusted figure at 24 weeks comes from an unpublished Phase 1 extension reported via press release. Phase 2 obesity and T2D trials are completed or ongoing and Phase 3 began in 2026, positioning it as a competitive obesity therapeutic with a mechanism similar to tirzepatide.
Compared With
8 comparisonsConditions Studied
3 entries- SLU-PP-332 for Exercise Intolerance SLU-PP-332 was developed as an exercise mimetic targeting ERR receptors. Mouse studies showed improved treadmill endurance and red…
- SLU-PP-332 for Metabolic Dysfunction ERR activation enhances mitochondrial biogenesis and oxidative metabolism in preclinical models. Theoretical applications include…
- SLU-PP-332 for Muscle Wasting Exercise mimetics have been proposed for sarcopenia, cachexia, and disuse atrophy where physical exercise is not possible. SLU-PP-…